Regenxbio Inc (RGNX)
Debt-to-equity ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 311,742 | 363,100 | 405,855 | 465,139 | 516,195 | 563,824 | 630,519 | 689,669 | 764,298 | 461,414 | 507,245 | 554,504 | 377,753 | 415,660 | 397,861 | 420,152 | 450,197 | 468,395 | 494,592 | 487,053 |
Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $311,742K
= 0.00
Regenxbio Inc has consistently maintained a debt-to-equity ratio of 0.00 across all quarters in the provided dataset, indicating that the company has not used any debt to finance its operations relative to its equity. This suggests that Regenxbio relies primarily on equity financing, which may indicate a lower level of financial risk and potential for financial distress. However, it is important to note that a zero debt-to-equity ratio may also imply missed opportunities for leveraging debt to potentially enhance returns for shareholders. Overall, a consistent zero debt-to-equity ratio reflects Regenxbio's conservative capital structure and financial stability.
Peer comparison
Dec 31, 2023